Form 4: Inhibrx Biosciences Director Kristiina Vuori Increases Stake in Company

Kristiina Vuori, a director at Inhibrx Biosciences, recently purchased additional shares of the company's common stock, increasing her beneficial ownership.

Summary

• On September 10, 2024, Kristiina Vuori, a director of Inhibrx Biosciences, acquired 179 shares of common stock at a price of $15 per share.
• On September 11, 2024, Vuori purchased an additional 6,457 shares of common stock at a weighted-average price of $15.07 per share, with prices ranging from $15.00 to $15.08.
• Following these transactions, Vuori's direct ownership in Inhibrx Biosciences increased to 13,776 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a director increasing their stake, which can be seen as a positive signal, but it's a routine transaction.

Positives

• A director increasing their stake in the company can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This is a routine disclosure of insider trading activity. It's common for directors and officers to buy or sell shares of their company, and these transactions are closely monitored by regulators and investors.

Stakeholder Impact

• The increased stake of a director may positively influence shareholder confidence.

Key Dates